What Changed
Price Move History
- Daily moves over 5%
- 4 6 sessions, January 27, 2026 to October 7, 2026
- Largest daily move
- -41% close of September 14, 2026
Company Description
DBV Technologies S.A. (DBVTF) is a French company whose securities are associated with American Depositary Shares (ADSs) trading under the symbol DBVT on The Nasdaq Stock Market LLC. Each ADS represents five ordinary shares with a nominal value of €0.10 per share. The company is organized in France and is registered with the U.S. Securities and Exchange Commission in connection with its Nasdaq listing.
According to its SEC filings, DBV Technologies S.A. has ordinary shares and American Depositary Shares registered under Section 12(b) of the Securities Exchange Act of 1934. The ADSs trade on The Nasdaq Stock Market LLC, while the ordinary shares are noted as being listed in connection with that ADS program. The company is identified in SEC records with Commission File Number 001-36697 and is based in France.
The available regulatory information highlights DBV Technologies S.A.’s status as a foreign private issuer with securities registered in the United States. Its filings include current reports on Form 8-K that disclose material corporate events, such as changes in the composition of its Board of Directors. These disclosures provide investors with insight into corporate governance developments and other significant matters affecting the company.
In a Form 8-K filed with the SEC, DBV Technologies S.A. reported the resignation of a member of its Board of Directors and of the compensation committee of the Board. The filing states that the resignation was effective immediately and that it was not the result of any dispute or disagreement with the company or the Board. The company also issued a press release regarding this event, which was furnished as an exhibit to the filing.
Because only limited descriptive information is available in the provided sources, public investors primarily rely on DBV Technologies S.A.’s SEC filings to understand its corporate structure, the nature of its listed securities, and key governance changes. The company’s presence on The Nasdaq Stock Market LLC through its ADSs indicates that it has chosen to access U.S. capital markets and comply with associated reporting obligations.
Stock listing and securities
DBV Technologies S.A. has ordinary shares with a nominal value of €0.10 per share and American Depositary Shares, each ADS representing five ordinary shares. The ADSs trade under the symbol DBVT on The Nasdaq Stock Market LLC. The ordinary shares are noted in SEC disclosures as being listed in connection with the registration of the ADSs on Nasdaq. This structure allows U.S. investors to gain exposure to the company’s equity through ADSs while the underlying ordinary shares remain issued by the French entity.
Regulatory reporting and governance
As reflected in its Form 8-K filing, DBV Technologies S.A. reports material corporate events to the SEC, including changes involving directors and certain officers. In one such filing, the company disclosed the resignation of a Board member and compensation committee member, clarifying that the resignation did not arise from any dispute or disagreement with the company or its Board. The company furnished a related press release as an exhibit to that report.
These filings illustrate how DBV Technologies S.A. communicates governance changes to the market. Investors can monitor such reports to follow developments in the composition of the Board of Directors and to understand how the company addresses its disclosure obligations under U.S. securities laws.
Use of SEC filings for research
Given the limited descriptive information in the provided data, DBV Technologies S.A.’s SEC filings are a primary reference for understanding its listed securities, regulatory status, and key corporate events. Filings such as Form 8-K identify the company’s jurisdiction (France), its Commission File Number, the nature of its listed securities, and specific events the company chooses or is required to disclose.
Investors researching DBV Technologies S.A. can review these documents to see how the company describes its securities, how it complies with Nasdaq-related reporting, and how it handles Board-level changes. Over time, the sequence of filings can provide a historical record of significant events affecting the company.
Stock Performance
DBV TECHNOLOGIES SA (DBVTF) closed at $1.98 on October 7, 2026. Over the past week, the price has lost 21.2%.
DBVTF Metrics & Rankings
Price returns through October 7, 2026. Month-to-date and YTD include the first trading day. Ranking links may use different dates.
Latest News
SEC Filings
DBV TECHNOLOGIES SA has filed 10 recent SEC filings, including 5 Form 8-K, 1 Form 4, 1 Form SCHEDULE 13G, 1 Form S-3ASR. The most recent filing was submitted on September 30, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all DBVTF SEC filings →
Financial Highlights
DBV TECHNOLOGIES SA generated $5.6M in revenue in FY2025, operating income reached -$147.1M, and net income was -$146.9M. Diluted earnings per share stood at -$1.05. The company generated -$121.2M in operating cash flow. The current ratio was 3.67, measuring current assets divided by current liabilities.
Upcoming Events
Short Interest History
Short interest in DBV TECHNOLOGIES SA (DBVTF) currently stands at 476.9 thousand shares, down 11.3% from the previous reporting period, representing 0.2% of the shares outstanding. Since October 2025, short interest has increased by 1878.7%.
Days to Cover History
Days to cover for DBV TECHNOLOGIES SA (DBVTF) currently stands at 5.3 days, down 60.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since October 2025, the figure has decreased by 99.5%. Across the settlements charted above, it has ranged from 1.0 to 1000.0 days.
DBVTF Company Profile & Sector Positioning
DBV TECHNOLOGIES SA (DBVTF) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC.